Abstract | BACKGROUND: METHODS: The study involved ten children with AS, normal renal function, and persistent proteinuria (>6 months; uPr/uCr ratio >1). SP 25 mg once a day for 6 months was added to existing ACE inhibitor treatment with or without angiotensin-II receptor blockade. Urine and blood samples were examined monthly. Urinary TGF-β1 levels were measured twice before and three times during SP treatment. Plasma renin activity (PRA) and serum aldosterone levels were also measured. In eight patients, uProt/uCreat was also assessed after 9 months and 12 months of SP treatment. RESULTS: After beginning SP therapy, all patients showed significant decrease in mean uProt/uCreat ratio (1.77 ± 0.8 to 0.86 ± 0.6; p < 0.001) and mean urinary TGF-β1 levels (104 ± 54 to 41 ± 20 pg/mgCreatinine; p < 0.01), beginning after 30 days of treatment and remaining stable throughout SP administration. PRA remain unchanged, and mean serum aldosterone increased from 105 ± 72 pg/ml to 303 ± 156 pg/ml (p < 0.001). The only side effect was gynecomastia in an obese boy. After 1 year of therapy, mean uProt/uCreat remains low (0.82 ± 0.48). CONCLUSIONS: Addition of SP to ACE-I treatment with or without angiotensin II receptor blokers (ARB) significantly reduced proteinuria. This was mediated by decreased urinary TGF-β1 levels and not associated with major side effects.
|
Authors | Marisa Giani, Antonio Mastrangelo, Roberta Villa, Stefano Turolo, Giuseppina Marra, Amedea Silvia Tirelli, Helmut Hopfer, Alberto Edefonti |
Journal | Pediatric nephrology (Berlin, Germany)
(Pediatr Nephrol)
Vol. 28
Issue 9
Pg. 1837-42
(Sep 2013)
ISSN: 1432-198X [Electronic] Germany |
PMID | 23748277
(Publication Type: Journal Article)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Mineralocorticoid Receptor Antagonists
- Transforming Growth Factor beta1
- Spironolactone
- Aldosterone
- Enalapril
- Creatinine
|
Topics |
- Adolescent
- Aldosterone
(blood)
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Blood Pressure
(physiology)
- Child
- Creatinine
(urine)
- Enalapril
(therapeutic use)
- Female
- Humans
- Kidney Function Tests
- Male
- Mineralocorticoid Receptor Antagonists
(therapeutic use)
- Mutation
(physiology)
- Nephritis, Hereditary
(drug therapy, genetics, urine)
- Proteinuria
(drug therapy, urine)
- Spironolactone
(therapeutic use)
- Transforming Growth Factor beta1
(urine)
- Treatment Outcome
- Young Adult
|